Acute or subacute neurologic disorders can be observed in patients receiving high-dose methotrexate therapy for lymphoblastic leukemia or malignant tumor. Impairment of biopterin metabolism leading to decreased availability of monoamine neurotransmitters has been suggest ed to explain methot rexate neurotoxicity. To investigate such a mechanism, we have measured prospectively by HPLC the concentra tions of total biopter in, homovanillic acid, and 5-hydroxyindo lacetic acid in cerebrospinal fluid of 57 children with acute lymphoblastic leukemia. A sequential analysis of cerebrospinal fluid was performed for each patient: cerebrospina l fluid samples were obtai ned before therapy and after each of the four high-dose methotrexate infusions during the CNS proph ylaxis phase. A significant increase of total biopterin conce ntrations in cerebrospinal fluid was observed after high-dose methotrexate therapy com pared with the pretreat ment values. No cumulative effect was noted. In contrast, no signifiChildren with leukemia or malignant tumor receiving intrathecal or i.v. MTX may develop acute or subacute encephalopathy (1, 2), suggesting a direct effect of the drug on the brain metabolism. The hypothesis of impaired neurotransmitter synthesis has been proposed to explain the occurrence of these abnormalities (3). The biogenic ami ne neurotransmitters are produced in the brain at a rate-limiting hydro xylation from precursor amino acids. Tetrahydrobiopt erin is the essential cofactor of this hydroxylation step. DHPR maintain s adequate leve ls of tetrahydrobiopterin, and the inherited deficiency of DHPR leads to impaired neurotransmitter amine synthesis and severe neurologic disease (4). It has been suggest ed that MTX,
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METHODS
Patients. Fifty-seven childr en (23 girls and 34 boys) with acute lymphoblastic leukemia from the pediatric hematology departments of Lille , Nantes, and Poitiers University Hospitals were treated between August 1989 and January 1993 according to the Children' s Leukemia Cooperative Group protocol (11) . The mean age of the patients was 6 y (range, 1 to 16 y; median, 5 y). After induction and consolidation phases, all children received daily 6-merc aptopurine and four i.v. high-dose MTX courses (5 g/m" every 2 wk) . Intrathecal administr ation of MTX was performed at the end of each MTX infusion after cerebrospinal fluid collection. All the patients were in complete remissi on and none of them had CNS involvement at the time of the MTX therapy. High-do se MTX was given as a 24-h i.v. infusion with alcaline hydration. Folinic acid rescue (15 mg/rrr' given orally every 6 h) was initiated 12 h after the end of MTX infusion. None of the patients had clinical evidence of neurologic dysfunction during the study. After randomization, 19 high-risk children received i.v. cytosine arabinosine (1 g/nr') administered 12 and 24 h after the start of each MTX infusion. All patients were observed sequentially befor e receiving any therapy and after the four MTX courses. Permission to include each child in the study was obtained by informed consent from the parents. The study was approved by the ethics committee of the Catholic Univers ity Hospitals of Lille.
Cerebrospinal fluid analysis. Cerebrospinal fluid samples were obtained by routine lumbar punctur e at initial diagnosis of hemopathy before any treatment and immediately at the end of each MTX infusion just before intrathecal therapy. After collection for standard cytoch emical analysis, a 1-mL cerebrospinal fluid sample was collected directly into a plastic tube and stored at -70°C until analysis. Cerebrospinal fluid levels of total biopterin, 5HIAA, and HVA were determined in a reference center by HPLC as previously described (12, 13) .
Statistics . Statistical analysis of the data was performed with SAS software (SAS Institute, Inc., Cary, NC). Normality of the values distribution was assessed using the Shapiro-Wilk test. Repeated measures analysis of variance was performed to test intrapatient differences between the five values of total biopterin, 5HIAA, and HVA (before and after the four MTX courses). Student-Newman-Keuls test was used if a significant difference was seen. t test was used to compare patients receiving cytosine arabinoside with those not receiving it.
Significance was evaluated at the p < 0.05 level.
RESULTS
For all patients, total biopterin, 5HIAA, and HVA concentrations were available before any treatment. Two hundred eighty-five cerebrospinal fluid samples from 57 patients were analyze d. Large interpatient var iations of total biopterin, 5HIAA, and HVA levels were observed (Table 1) (14) . Tetrahydrobiopterin is the required cofactor of hydroxy lases for biogenic amine synthesis from the amino acid precur sors tyrosine and tryptophan (Fig . 1) . DHPR is essential for maintaining efficient tetrah ydrobiopterin levels. This regenerating system of the cofactor of hydroxylases is inhibited in vitro by high concentrations of MTX (5). Inhibition of DHPR in the brain by MTX leading to tetrahydrobiopterin deficiency and therefore to impairment of biogenic amine synthesis might explain the occurrence of neurologic signs observed in a few patients after MTX therapy (3).
Hyperphen ylalanin emia and increased levels of total biopterin were reported in serum of patients receiving systemic high-do se MTX (15, 16) . In addition , serum phenylalanine levels normalized or fell significantly after tetrahydrobiopterin administr ation in patients with hyperph enylalaninemia induced by MTX therapy (17) . Hyperphenylalaninem ia and high total biopterin concentrations are also observed in serum of children with inherited DHPR deficiency (18) . These reports strongly suggest impairment of DHPR activity in peripheral compartments after MTX therapy. Pinkerton et al. (7) reported a rise of biopterin levels in serum but not in cerebrospinal fluid of children with acute lymphobl astic leukemia undergoing induction (including intrathec al MTX) or maintenance (including oral or intramuscular MTX) chemotherap y. This observation can be explained by the poor diffusion in the CNS of low-dose MTX administered by venous or intrathecal route. However, these authors reported increased biopter in concentrations in cerebros pinal fluid of children who had completed 2 y of maintenance therapy, suggesting a cumulative effect of repeated MTX administrations. We chose to conduct our prospective study in children undergoing systemic high-dos e MTX because pharmacokinetic studies demonstrated that i.v. 5 gjm 2 MTX can provide drug level s in CNS that can potentially inhibit cerebral DHPR (19) . The present study shows a significant rise of biopterin levels in cerebro spinal fluid after 5 gjm 2 MTX infusion. Such biochemical findings are similar to those observed in inherited DHPR deficienc y (18) . In these patients , an increased level of total biopterin reflects the accum ulation of dihydrobi opterin with a concomitant decrease in tetrahydrobiopterin. Because of high instability of reduced biopterins, measurement of tetrahydrobiopterin in cerebrospin al fluid was not performed in our multic entric study. However, we previous ly reported a slight but significant decrea se of tetrahydrobiopterin in a selected group of children receiving i.v. high-dose MTX therapy (16) . In contrast, Hyland et al. (20) reported the absence of decreased tetrahydrobiopterin concentrations in a few patients receiving intrathecal MTX . No cumulative effect of the successive courses of MTX on the total biopterin level in cerebrospina l fluid was noted in our study. However, our patien ts were observed over a period of a only few month s.
No significant variation of cerebrospinal fluid neurotransmitter metabolite levels was observed in this study except a modest but significant increase in HVA levels after the second course of high-dose MTX. The absence of reduced concentrations of monoamine catabolites can be explained by an insufficient decrease of tetrahydrobiopterin to induc e alteration of monoamine metabolism. Individual analysis revealed a transient decrease of these metabolites in six patients , but none of them experienced neurologic abnormalities. Howe ver, such metabolic change s constitute a propen sity for the occurrence of neurologic abnormalities. We previously report ed the occurrence of acute neurologic dysfunction in a child with decreased 5HIAA and HVA concentrations in cerebrospinal fluid after high-dose i.v. MTX (3 g/m") infusion (21) . Individual susceptibility can explain the occurrence of such neurologic perturbations in a context of low 5HIAA and HVA levels. In contrast, Silverstein et al. (8) reported a gradual rise of 5HIAA and HVA levels in leukemic children after 1 mo of treatment with weekly intrathecal MTX, but it was impossible to determine whether these variations are caused by delayed egress from cerebrospinal or enhanced turnover. Although cytosine arabin oside has no reported effect on biogenic amine metabolism, these authors related an unexpe cted decrease of 5HIAA and HVA levels in five of six patients who had received intrath ecal cytosine arabinoside alone . Interestingly, high-dose cytosine arabinoside systemic infusions, which provide high drug concentrations in the CNS, had no significant influence on these metabolite concentrations in our study. Individua l analysis revealed that among our six patients with a transient decrease of 5HIAA and HVA levels only two had received cytosine arabinoside in associat ion with high-dose MTX .
The present work demonstrated an effect of high-dose MTX infusions on biopterin metabolism in the CNS but the absence of stigmas of significant impairment of monoamine synthesis. However, individual analysis showed a decrease in cerebrospinal monoamine catabolite levels in a few children but without neurologic dysfunction. The data in this prospectiv e study are comp atible with the hypothesis of an inhibition of the regen-erating system of biopterin after systemic MTX therapy. We previously reported a successful substitutive treatment with neurotransmitter precursors and tetrahydrobiopterin in a child with a subacute encephalopathy related to a defect of tetrahydrobiopterin synthesi s after MTX therapy (22) . Because of potenti al replacement therapy, additional investigations are needed in children with acute neurologic dysfunction after high-dose MTX therapy.
